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SERODIAGNOSIS OF NEUROCYSTICERCOSIS IN PATIENTS WITH EPILEPTIC SEIZURE USING ELISA
AND IMMUNOBLOT ASSAY
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SUMMARY
Sera from 88 patients from Santa Catarina and São Paulo states of Brazil, with epileptic seizures who underwent cerebral
computed tomography (CT) were analyzed for the detection of antibodies to T. solium cysticercus by ELISA and Immunoblot (IB)
with the following antigens: Taenia solium cysticercus total saline (Tso), Taenia crassiceps cysticercus vesicular fluid (Tcra-vf)
and T. crassiceps cysticercus glycoproteins (Tcra-gp). ELISA carried out with Tso, Tcra-vf and Tcra-gp antigens showed 95%,
90% and 80% sensitivities, respectively, and 68%, 85% and 93% specificities, respectively. In the epileptic patients group, ELISA
positivity was 30%, 51% and 35% with Tso, Tcra-vf and Tcra-gp antigens respectively. Considering the IB as the confirmatory
test, the positivity was 16% (14/88) in the epileptic patients total group and 22% (12/54) in the epileptic patients with positive CT
and signals of cysticercosis. We found a significant statistical correlation among ELISA or IB results and the phase of the disease
when any antigens were used (p < 0.05). We emphasize the need to introduce in the laboratory routine the search for neurocysticercosis
(NC) in patients presenting with epileptic seizures because of the high risk of acquiring NC in our region and its potential cause of
epilepsy.
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INTRODUCTION
Neurocysticercosis (NC), an infection caused by Taenia solium
cysticerci lodged in the central nervous system (CNS), is recognized
as a leading cause of symptomatic epilepsy in developing countries3,19.
The etiologies of epilepsy are many but Brazilian studies using
computed tomography (CT) found that almost 30% of all epilepsy is
related to cysticercosis2. However most of patients with NC are
asymptomatic6. When symptomatic, NC can also be presented as
intracranial hypertension syndrome, cysticercal meningitis,
hydrocephalus and signals of spinal cord compression. This clinical
pleomorphism is mainly related to the number, size, type,
developmental stage and site of cysts in the nervous system, as well as
the host inflammatory response12. Epileptic seizures seem to be more
common in patients presenting with multiple lesions14 and these may
occur at the time of cyst degeneration7.
The diagnosis of NC relies on clinical, epidemiological and
laboratory criteria and on imaging examinations such as CT and
magnetic resonance imaging (MRI)11. The main limitation of
immunological techniques is the difficulty in obtaining antigens from
T. solium larvae in a large amount, enough to undergo purification
processes, which are need to reduce the nonspecific or cross-reactive
fractions from the total antigenic extracts. Some studies demonstrated
that T. solium from pig infection and T. crassiceps which can be
maintained in mice, share antigenic components, including those of
low molecular mass peptides (18 and 14 kDa)8,15. T. crassiceps larvae,
which are easily maintained in the laboratory by intraperitoneal passage
through female BALB/c mice, were shown to be an important alternative
source of such antigen components5,17,22.
In order to evaluate the performance of different antigens from T.
solium and T. crassiceps cysticerci in the diagnosis of
neurocysticercosis, sera from epileptic patients were analyzed for
detection of antibodies IgG to T. solium cysticerci by ELISA and
immunoblot assay. Also, the potential capability of these techniques
using those antigens in order to discriminate the phases of the NC in
epileptic patients was investigated.
MATERIALS AND METHODS
Serum samples. Epileptic patients group: A total of 88 serum
samples were collected from patients suffering from epilepsy who
underwent CT. Fifty four (54) out of 88 had suggestive signals of
neurocysticercosis (12 with active or mixed lesions and 42 with calcified
lesions), whereas 34 remainder patients showed negative results in the
CT exam. Eighty patients were from the Clinica Multidisciplinar de
Epilepsia, Estado de Santa Catarina, SC, Brasil and eight patients
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were from the Hospital das Clínicas (HC), Universidade de São Paulo,
SP, Brasil (HC-USP).
Control Groups: Twenty serum samples from patients with NC
confirmed by imaging exams (CT and/or MRI) and serologic assays
(ELISA and IB), obtained from BUENO’s study5, were used as positive
control group (NC group). Fifty three serum samples from blood donors
were used as negative control group (non NC group), distributed as
follow: 20 samples were kindly supplied by Biolab-Mérieux Laboratory
SA, São Paulo, Brazil and 33 samples were colletecd from Hemotherapy
Service of Hospital Universitário, Universidade Federal de Santa
Catarina, Brazil.
Inform consent was obtained from all adult participants and from
parents of minors and the research was approved by the Ethics
Committee of Universidade Federal de Santa Catarina, SC, Brazil
(process number 007/98) and Faculdade de Ciências Farmacêuticas,
Universidade de São Paulo, SP, Brazil (process number 035/00)
according to Resolution 196/96 of the National Health Council, Ministry
of Health, Brasília, Brazil.
Parasite antigens: A total saline extract of T. solium cysticerci
(Tso) and vesicular fluid of T. crassiceps cysticerci (Tcra-vf) were
obtained as described before16. Purified glycoproteins of T. crassiceps
cysticercus (Tcra-gp) were isolated by affinity chromatography, using
a Concanavalin A-Sepharose 4B column17.
Enzyme-linked immunosorbent assay (ELISA): The ELISA was
performed according to previously standardized protocols: with Tso and
Tcra-vf5 and with Tcra-gp15. Determination of the cut-off values was
based on the analysis of the diagnostic efficiency, according to the Youden
index23 calculated for the absorbance values of the control groups (mean
± n standard deviations). Reactivity index (RI) values were calculated
by dividing the mean absorbance value of two readings from each sample
assayed by the cut-off value corresponding to each antigen used. Samples
with RI > 1 were classified as reactive. Among 20 samples from NC
group, 19 (95%), 18 (90%) and 16 (80%) gave positive results in ELISA
using respectively, Tso, Tcra-vf and Tcra-gp. Among 53 serum samples
from Non NC Group, only 20 samples from Biolab-Mérieux Laboratory
SA, São Paulo, Brazil were used to calculate the cut-off value and three
of them gave positive results in ELISA using Tcra-vf.
Immunoblot assay (IB): The IB was performed with the Tcra-vf
antigen, as described before5. In order to define the positivity criterion
for diagnosis of cysticercosis by the IB, we studied the reactivity to
the Tcra-vf peptide antigens of 20 samples from NC group and 20
samples from Biolab-Mérieux Laboratory SA, São Paulo, Brazil. The
molecular masses of the antigenic fractions were calculated on the
basis of molecular masses standards and the respective relative fronts
(Rf), with the aid of the Excel program. All 20 samples from NC group
reacted to the antigenic peptides 18-14 kDa of Tcra-vf and conversely,
none of the 20 samples from Non NC Group assayed reacted to the
same antigenic peptides. Thus we assumed that any reaction against
the low molecular mass range of 18-14 kDa of Tcra-vf antigen should
be considered specific.
Statistical analysis. To determine the proportion or association
the Q-square test was used or the Fisher exact test. The significance
level adopted in the whole study was 5%10.
RESULTS
The ELISA and IB assay results obtained for serum samples from
epileptic patients according to the CT exam result, type of lesion and
antigen used are presented in Table 1.
The ELISA results with sera from the control groups and from the
epileptic patients, according to the lesion type detected in the CT exam
and according to the antigen used, are presented in Figure 1. Among
53 samples from Non NC group, 16 (30%), 8 (15%) and 5 (9%)
presented positive results with ELISA using Tso, Tcra-vf and Tcra-gp,
respectively (Fig. 1), and three (6%) were positive in the IB assay
(data not shown). The IB assay with serum samples from epileptic
patients is shown in Figure 2. Nonspecific reactions were observed
with molecular sizes higher than the specific (18-14 kDa) peptides.
The results of the serologic techniques (ELISA and IB) showed a
significant statistical correlation with the type of lesion (active/mixed
or calcified) or absence of lesions detected by the CT exams (p < 0.05).
DISCUSSION
The diagnosis of NC is a relevant subject because of its
immunopathological complexity, being one of the
most frequently studied parasitosis in recent years.
Epilepsy is the more common manifestation of NC
but as it may have other cause than NC, the
serological techniques emerge as of great importance
to help the diagnosis of this parasitosis, together with
the image exams. The symptoms of NC are
nonspecific and depends on the number of cysticercus
alive, in degeneration or already calcified, the
location of the lesions and the host’s immune
response. The results of serologic techniques are also
directly related to these data and could explain why
their efficiency varies according to authors.
In our study, ELISA carried out with Tcra-vf or
Tcra-gp showed a good screening and diagnostic
performance for the diagnosis of cysticercosis in
Table 1
Positive results of enzyme-linked immunosorbent assay (ELISA) and immunoblot assay (IB) in
epileptic patients from Santa Catarina and São Paulo states, Brazil, according to Computed
Tomography (CT) exam, type of lesion and antigen used
ELISA IB
No. Tso Tcra-vf Tcra-gp Tcra-vf
tested n+ (%) n+ (%) n+ (%) n+ (%)
Active/mixed lesions 12 10 (83) 12 (100) 12 (100) 11 (92)
Calcified lesions 42 8 (19) 18 (43) 10 (24) 1 (2)
Total positive CT 54 18 (33) 30 (56) 22 (41) 12 (22)
Negative CT 34 8 (24) 15 (44) 9 (26) 0 (0)
Total epileptics 88 26 (30) 45 (51) 31 (35) 14 (16)
Tso = Taenia solium cysticercus total saline; Tcra-vf = Taenia crassiceps cysticercus vesicular fluid;
Tcra-gp = T. crassiceps cysticercus glycoproteins purified by affinity chromatography with lectin.
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patients with proved NC (active/mixed lesions). The IB also showed a
very sensitive method in the diagnosis of NC from viable cysts, though
it failed to detect antibodies in a single serum sample from a patient
with mixed lesion.
The results obtained by serologic techniques in the study of sera
from patients with calcified lesions are difficult to be interpreted once
there are different etiologic agents which can cause epilepsy. As only
one sample from calcified lesions was reactive to the IB (with high RI
value), we suppose that in our sampling either the antibody levels were
lower than the sensitivity of the IB or the ELISA results were false
positive. In the non NC group we obtained positive results mainly with
the Tso antigen. The specificity of the ELISA with Tcra-vf has been
reported as 80% and 96% by BUENO et al.5 and BRAGAZZA et al.4,
respectively, while PERALTA et al.17 reported 98% specificity for ELISA
with 14 kDa glycoprotein of T. crassiceps. In this study the Tcra-gp
antigen showed similar sensitivity and better specificity than that of
Tcra-vf, so Tcra-gp seems to be the best choice to be attempt in order to
improve the specificity of ELISA for screening purpose and efforts are
underway through purification of the specific and immunodominant
antigens. More recently, ELISA using 18-14 kDa proteins from T.
crassiceps cysticercus obtained by immunoaffinity chromatography
showed a good performance and high specificity for serum samples
becoming not necessary the use of IB as confirmatory test9.
According to BERN et al.1, the IB developed by the Centers for
Disease Control - CDC, Atlanta, USA using purified glycoprotein21 is
highly sensitive in patients with active multiple lesions and conversely,
is less sensitive in patients with single lesion and with those with
calcified lesions. The majority of the samples analyzed in this study
belongs to patients with calcified lesions and information about number
of cysts lodged in the CNS of those with enhancing intracranial lesions
was not available.
The positivity of the ELISA in the sera from epileptic patients
without detectable lesions by CT exam may be attributed to the low
sensitivity of the CT to detect microlesions; presence of cysticerci
causing no successful infection, but able to produce antibodies and the
lack of specificity of the serologic technique. We have previously
studied sera from patients with different helminthiases against different
helminth antigens used in ELISA and IB: cross-reactivities occurred
mostly with the use of antigens belonging to phylogenetically related
parasite species13.
The results of ELISA and IB had a good correlation with CT
findings (active, calcified or absence of lesions), that is to say these
techniques presented good diagnostic features to discriminate the phase
of the disease (p < 0.05). As detection of calcified cysts showed to be
relatively low, a positive result is highly indicative of active disease,
an important fact to make a decision about a treatment.
The challenges for the population control of cysticercosis and
epilepsy in the developing countries depend on a reliable and low cost
immunological techniques which should be performed with serum
samples.
Because of the socioeconomic peculiarities with disseminated pig
rearing, the south of Brazil is considered area of high risk of acquiring
cysticercosis. TREVISOL-BITTENCOURT et al.20 reported 24% of
NC cases in epileptic patients who underwent CT during 1995 and
1996, admitted to the Chapecó Hospital, west region of Santa Catarina
(SC). In a retrospective study conducted in an Epilepsy Clinic from
Florianópolis, SC, RIGATTI & TREVISOL-BITTENCOURT18 reported
NC as one of the most frequent and relevant etiology of epilepsy.
This study represents the first serology survey on NC carried out
in Santa Catarina state and its continuity can play an important role in
the diagnosis and epidemiology of the disease. The association of
neuroimages suggestive of NC with a history of epilepsy in our region
led us to suggest the need to introduce the search for NC in the patients
suffering from epilepsy, by means of a trustworthy and available
diagnostic methods in the laboratory routine.
Fig. 1 - Reactivity Index values (RI) of ELISA using: Taenia solium cysticercus total saline
(Tso); Taenia crassiceps cysticercus vesicular fluid (Tcra-vf) and T. crassiceps cysticercus
glycoproteins purified by affinity chromatography with lectin (Tcra-gp) with the serum
samples from epileptic seizure patients (n = 88), according to the lesion type detected in the
computed tomograph exam and from the control groups (NC group = Neurocysticercosis
group; non-NC group = Normal group). The bars mean average RI values.
Fig. 2 - Immunoblot assay using vesicular fluid of Taenia crassiceps cysticerci and serum
samples from epileptic patients. C+ positive control; C- negative control; positive results
(lanes 1 to 3) and negative results (lanes 4 to 6). Molecular masses (kDa) are shown at the
left. The arrows show specific reactions with 18-14 kDa peptides.
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RESUMO
Sorodiagnóstico da neurocisticercose em pacientes com crises
epiléticas, por meio de ELISA e immunoblot
Amostras de soro de 88 pacientes dos Estados de Santa Catarina e
São Paulo, Brasil, com crises epilépticas e que se submeteram a exame
de Tomografia Computadorizada (TC), foram examinadas para detecção
de anticorpos anti-cisticercos de Taenia solium por meio de ELISA e
Immunoblot (IB) utilizando-se os seguintes antígenos: extrato salino
total de cisticercos de T. solium (Tso); líquido vesicular de Taenia
crassiceps (Tcra-vf) e glicoproteínas purificadas de cisticercos de T.
crassiceps (Tcra-gp). Os resultados de ELISA com os antígenos Tso,
Tcra-vf e Tcra-gp mostraram 95%, 90% e 80% de sensibilidade,
respectivamente, e 68%, 85% e 93% de especificidade, respectivamente.
No grupo de pacientes epilépticos, a positividade do ELISA foi 30%,
51% e 35% com os antígenos Tso, Tcra-vf e Tcra-gp, respectivamente.
Considerando o IB como teste confirmatório, a positividade foi de
16% (14/88) no grupo total de pacientes epilépticos e 22% (12/54) no
grupo de pacientes epilépticos com TC positiva e sinais clínicos
compatíveis com neurocisticercose. Foi encontrada correlação
estatística significativa entre os resultados de ELISA ou IB e a fase da
doença com quaisquer dos antígenos utilizados (p < 0,05). Os resultados
indicam a necessidade de introduzir na rotina dos laboratórios o
diagnóstico de neurocisticercose nos pacientes com convulsões
epilépticas devido ao elevado risco de aquisição da cisticercose em
nossa região e sua participação na etiologia da epilepsia.
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